Recently, Panaampon et al. found that trastuzumab exerts multiple mechanisms against HER2-altered CCA, including direct growth inhibition, complement-dependent cytolysis (CDC), ADCC, and ADCP in both in vitro and CCA patient-derived xenograft (PDX) models [73]. Here, ERBB2 is linked to cholangiocarcinoma.